These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26174905)

  • 1. Donor screening reduces the isoagglutinin titer in immunoglobulin products.
    Siani B; Willimann K; Wymann S; Marques Antunes A; Widmer E
    Transfusion; 2015 Jul; 55 Suppl 2():S95-7. PubMed ID: 26174905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.
    Siani B; Willimann K; Wymann S; Marques AA; Widmer E
    Biol Ther; 2014 Dec; 4(1-2):15-26. PubMed ID: 24841428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
    Romberg V; Hoefferer L; El Menyawi I
    Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.
    Gerber S; Gaida A; Spiegl N; Wymann S; Antunes AM; Menyawi IE; Zurbriggen B; Hubsch A; Imboden M
    BioDrugs; 2016 Oct; 30(5):441-451. PubMed ID: 27646589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products.
    McVey J; Baker D; Parti R; Berg R; Gudino M; Teschner W
    Transfusion; 2015 Jul; 55 Suppl 2():S98-104. PubMed ID: 25981342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products.
    Hoefferer L; Glauser I; Gaida A; Willimann K; Marques Antunes A; Siani B; Wymann S; Widmer E; El Menyawi I; Bolli R; Spycher M; Imboden M
    Transfusion; 2015 Jul; 55 Suppl 2():S117-21. PubMed ID: 26174889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.
    Mallick R; Hubsch A; Barnes DG
    Transfusion; 2018 Dec; 58(12):2752-2756. PubMed ID: 30284263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.
    Shebl A; Gabriel S; Van Dinther K; Hubsch A; Lawo JP; Hoefferer L; Welsh S
    Transfusion; 2020 Jun; 60(6):1278-1286. PubMed ID: 32410287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis.
    Bellac CL; Hottiger T; Jutzi MP; Bögli-Stuber K; Sänger M; Hanschmann KM; Keller-Stanislawski B; Funk MB
    Transfusion; 2015 Jul; 55 Suppl 2():S13-22. PubMed ID: 26174892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study.
    Wallenhorst C; Patel A; Shebl A; Hubsch A; Simon TL; Martinez C
    Transfusion; 2020 Jul; 60(7):1381-1390. PubMed ID: 32488887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of isoagglutinins in immunoglobulins for intravenous application by flow cytometry.
    Bürzle M; Hubsch A; Spiegl N; Roten T; Marques A; Martig L; Shebl A; Stadler D
    Anal Biochem; 2020 Feb; 591():113534. PubMed ID: 31821802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-A and anti-B: what are they and where do they come from?
    Branch DR
    Transfusion; 2015 Jul; 55 Suppl 2():S74-9. PubMed ID: 26174901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis.
    Cen SY; Branch DR
    Transfusion; 2020 Feb; 60(2):250-255. PubMed ID: 31837028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group O blood donors in Iran: evaluation of isoagglutinin titers and immunoglobulin G subclasses.
    Arabi S; Moghaddam M; Pourfathollah AA; Aghaie A; Mosaed M
    Immunohematology; 2021 Mar; 37(1):5-12. PubMed ID: 33962489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin.
    Salvatore A; Esin S; Batoni G; Ascione E; Farina C; Nardini C
    Transfusion; 2015 Jul; 55 Suppl 2():S110-6. PubMed ID: 26174888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful ABO incompatible living donor liver transplantation in a patient with high isoagglutinin titer using high-dose intravenous immunoglobulin.
    Ikegami T; Taketomi A; Soejima Y; Iguchi T; Sanefuji K; Kayashima H; Yoshizumi T; Harada N; Maehara Y
    Transplant Proc; 2007 Dec; 39(10):3491-4. PubMed ID: 18089417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange.
    Curley C; Pillai E; Mudie K; Western R; Hutchins C; Durrant S; Kennedy GA
    Transfusion; 2012 Feb; 52(2):291-7. PubMed ID: 21848968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
    Josephson CD; Castillejo MI; Grima K; Hillyer CD
    Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange.
    Uchiyama H; Mano Y; Taketomi A; Soejima Y; Yoshizumi T; Ikegami T; Shirabe K; Maehara Y
    Transplantation; 2011 Nov; 92(10):1134-9. PubMed ID: 21946174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor.
    Kim JM; Kwon CH; Joh JW; Kang ES; Park JB; Lee JH; Kim SJ; Paik SW; Lee SK; Kim DW
    J Hepatol; 2013 Dec; 59(6):1215-22. PubMed ID: 23928408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.